Basic Company Data Data as of: March 24, 2011 Current Price $32.

72
Symbol MRK MERCK & CO. INC. H&C Composite Score
Description Merck & Co., Inc. is a global pharmaceutical company that discovers, develops,
Neutral
manufactures, and markets a broad range of human and animal health products.
Merck's products include a treatment for elevated cholesterol, a treatment for
male pattern hair loss, a preventive treatment for osteoporosis, a treatment for
2.6
hypertension, and a treatment for allergic rhinitis.

Sector Health Care

Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 2/3/2011 Technical Score Fundamental Score
Earnings Date 5/4/2011 IPO Date #N/A N/A
Fundamentals Technicals
Market Cap. $100.9 B BETA 0.55 Price $32.72 MACD Oversold
Price/Earnings 9.57 1Yr. EPS Growth Rate % 6.46% 50-Day MA $33.11 Stochastics Trend Up
Forward Price/Earnings 8.54 5Yr. Avg. EPS Growth Rate % 9.86% 200-Day MA $35.13 RSI Signal Trend Up
Price/Book 1.85 EPS Growth QoQ 11.39% 50/200 Day MA -$2.02 S/T Trend Up
Forward PEG Ratio 1.57 Revenue Growth QoQ 19.82% Volume Pressure 0.58 L/T Trend Down
Return on Equity 16.12 Dividend Yield 4.65% Average Daily Volume 17,145,270 Bull / Bear Bull Trend
LT Debt/Equity 28.47% Cash Flow Per Share 2.76 M-Score (0 - 100%) 10%
H&C Fundamental Score 1.8 H&C Technical Score 0.8
Ownership Data
Inst. Buy/Sell Ratio 1.90 Management Ownership 0.04% 50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings -0.11% Short Interest Ratio 0.81 20 Day Moving Average S/T Resistance L/T Resistance

MERCK & CO. INC. $39

$38

$37

$36

$35

$34

$33

$32

$31

5.0
Bull Trend Bear Trend

0.0

-5.0
1.5
Up / Down Volume Ratio
1.0
0.5
0.0
1,000

500

0
29-Nov-10 13-Dec-10 28-Dec-10 11-Jan-11 26-Jan-11 9-Feb-11 24-Feb-11 10-Mar-11 24-Mar-11
Volume x100,000
Fundamentals
MERCK & CO. INC.
1
Earnings Per Share 2
Reported Estimate Target Price 19 Reported Estimate
$1.20 $60

$1.00 $50

$0.80 $40

$0.60 $30

$0.40 $20

$0.20 $10

$0.00 $0

Total Revenues 1
Reported Estimate
Ownership EPS & Revenue Growth
Investment Advisor 89.54% Quarter EPS Growth Rev. Growth
$14,000
Pension Fund (ERISA) 4.01% FQ1 2009 -17% -8%
Hedge Fund Manager 2.45% FQ2 2009 -3% -3%
$12,000
Insurance Company 1.72% FQ3 2009 11% 2%
Mutual Fund Manager 1.30% FQ4 2009 -10% 67%
$10,000 Bank 0.56% FQ1 2010 12% 112%
Unclassified 0.15% FQ2 2010 4% 92%
$8,000 Corporation 0.13% FQ3 2010 -4% 84%
FQ4 2010 11% 20%
$6,000
Top Holders and % Outstanding Forward Growth Estimates
$4,000 CAPITAL WORLD INVEST 6.84% Quarter EPS Growth Rev. Growth
CAPITAL RESEARCH GLO 5.25% FQ1 2011 2% -1%
STATE STREET CORP 3.79% FQ2 2011 8% 1%
$2,000
VANGUARD GROUP INC 3.59% FQ3 2011 9% 1%
WELLINGTON MANAGEMEN 3.01% FQ4 2011 11% -1%
$0
BLACKROCK INSTITUTIO 2.52%
DODGE & COX 1.89%
FIDELITY MANAGEMENT 1.77%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue

Yearly Yearly
Segment Name FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 Segment Name FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
United States 20,226.00 14,401.20 13,370.50 14,690.90 13,776.80 Pharmaceutical $39,811.00 $25,236.60 $22,019.90 $22,142.50 $20,442.40
Europe, Middle East and Africa 13,497.00 7,093.10 5,773.80 5,159.00 4,977.10 Animal Health $2,941.00 $494.00 $81.80 $258.60 #N/A N/A
Rest of World 8,496.00 3,508.40 2,882.50 2,814.60 2,403.10 Consumer Health $1,342.00 $149.00 #N/A N/A #N/A N/A #N/A N/A
Japan 3,768.00 2,425.60 1,823.50 1,533.20 1,479.00 Alliance and Other $1,252.00 $1,548.00 $1,600.00 $1,700.00 $1,800.00
Corporate, Divested Third-Party and Other $641.00 #N/A N/A $148.60 $96.60 $393.60

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry or
security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments disc ussed. Please click for detailed
disclosures and additional information about our stock ratings and scoring.

3/24/2011